

Antibiogram 2024 (January-December 2023) - Sanford Fargo ICU Patients
(All Sources)

	<<13 isolates		<30 isolates		
Organism	<i>Enterococcus faecalis</i>	<i>Enterococcus faecium</i>	<i>Staphylococcus aureus</i> MSSA	<i>Staphylococcus aureus</i> MRSA	<i>Streptococcus pneumoniae</i>
Total isolates	31	13	92	42	27
Susceptible Isolates					
Benzylpenicillin	100%	-	32%	0%	100%
Ampicillin	100%	15%	-	-	-
Oxacillin	-	-	100%	0%	-
Ceftriaxone	-	-	-	-	100%
Gentamicin	74% (HLS)	92% (HLS)	98%	100%	-
Ciprofloxacin	83%	15%	93%	33%	-
Levofloxacin	83%	15%	94%	33%	100%
Clindamycin	-	-	88%	73%	92%
Erythromycin	32%	-	76%	35%	70%
Linezolid	100%	-	100%	100%	-
Nitrofurantoin (Urine)	100%	31%	100%	97%	-
Rifampicin	-	-	98%	97%	-
Tetracycline	-	46%	94%	92%	-
TMP/SMX	-	-	96%	95%	88%
Vancomycin	100%	38%	100%	100%	-
Daptomycin	-	100% (8 tested)	-	-	-

* ≤ 30 organisms may lack statistical validity (Clinical and Laboratory Standards Institute [CLSI] guidelines M39A4E document)
HLS: High Level Synergy

Antibiogram 2024 (January-December 2023) - Sanford Fargo ICU patients
(All Sources)

	<30 isolates*		<30 isolates	<<30 isolates*		<<30 isolates*
Organism	<i>Enterobacter cloacae</i> *	<i>E. coli</i> *	<i>Klebsiella pneumoniae</i> *	<i>Haemophilus influenzae</i>	<i>Pseudomonas aeruginosa</i>	<i>Stenotrophomonas maltophilia</i>
Total Isolates	28	80	24	16	74	18
Susceptible Isolates						
Amoxicillin/Clavulanic acid	-	83%	95%	-	-	-
Ampicillin	-	59%	-	81%	-	-
Ampicillin/Sulbactam	-	-	-	-	-	-
Piperacillin/Tazobactam	66%	96%	92%	-	80%	-
Cefazolin	-	87%	92%	-	-	-
Cefepime	96%	95%	96%	-	86%	-
Cefoxitin	-	93%	92%	-	-	-
Ceftazidime	60%	95%	96%	-	89%	27%
Ceftriaxone	64%	94%	96%	100%	-	-
Amikacin	100%	100%	100%	-	96%	-
Gentamicin	92%	89%	100%	-	-	-
Tobramycin	92%	89%	100%	-	99%	-
Nitrofurantoin (Urine)	74%	97%	17%	-	-	-
Ertapenem	100%	100%	100%	-	-	-
Meropenem	96%	100%	100%	100%	88%	-
Ciprofloxacin	96%	89%	100%	-	86%	-
Levofloxacin	96%	91%	96%	100%	84%	100%
TMP/SMX	88%	85%	100%	50%	-	94%

*Includes ESBL/CRE (If applicable)
≤ 30 organisms may lack statistical validity (Clinical and Laboratory Standards Institute [CLSI] guidelines M39A4E document)